NCT04444362View on ClinicalTrials.gov

Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cardiovascular DiseaseCardiopulmonary Bypass
Interventions
DRUG

Intestinal Microbiota Transplant (IMT) Capsules

Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days

Trial Locations (5)

210029

The First Affiliated Hospital of Nanjing Medical University, Nanjing

Unknown

Beijing Anzhen Hospital, Beijing

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

West China Hospital of Sichuan University, Chengdu

Shanghai East Hospital, Tongji University, Shanghai

Sponsors
All Listed Sponsors
collaborator

Beijing Anzhen Hospital

OTHER

collaborator

Shanghai East Hospital of Tongji University

OTHER

collaborator

West China Hospital

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Nanjing Medical University

OTHER

NCT04444362 - Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV) | Biotech Hunter | Biotech Hunter